secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112904
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

KalVista shareholders elect directors, ratify auditor, approve say-on-pay at 2024 annual meeting
--------------------------------------------------------------------------------

- William Fairey and Nancy Stuart elected as Class III directors with 30.2M and 19.3M votes 'For', respectively; Stuart faced 11.7M votes 'Against'.
- Deloitte & Touche ratified as independent auditor for FY ending April 30, 2025 with 39.3M votes 'For'.
- Advisory say-on-pay proposal approved with 26.6M 'For', 4.5M 'Against'.
- Broker non-votes of 8.3M shares recorded for director election and say-on-pay proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024112904/0000950170-24-112904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024112904/kalv-20241003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer